AR016502A1 - Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas. - Google Patents

Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas.

Info

Publication number
AR016502A1
AR016502A1 ARP990103678A ARP990103678A AR016502A1 AR 016502 A1 AR016502 A1 AR 016502A1 AR P990103678 A ARP990103678 A AR P990103678A AR P990103678 A ARP990103678 A AR P990103678A AR 016502 A1 AR016502 A1 AR 016502A1
Authority
AR
Argentina
Prior art keywords
sulfamates
biogenic
sulfamate
replacement therapy
hormone replacement
Prior art date
Application number
ARP990103678A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR016502A1 publication Critical patent/AR016502A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de sulfamatos de estrogenos biogénicos para la administracion oral y discontinua en una terapia de reemplazo de hormonas (HRT). Dosis discontinuas sonadministradas a intervalos de 2 a 40 días. Administracion adicional de gestágenos es también proyectada preferiblemente de manera continua desde un implante oun dispensador intrauterino (IUD). Los sulfamatos de estrogeno biogénico usados son sulfamatos de estrona, sulfamato de estradiol, sulfamato de estriol, o unN-acil sulfamato de esterona, estradiol o estriol conteniendo hasta 7C-átomos en su cadena acílica, o una combinacion de dos o más de dichos ingredientesactivos. Dichos gestágenos son levonogestrel, desogestrel, noretisterona, acetato de ciproterona, acetato de clormadinona, dienogest, drospirenona, o unacombinacion de dos o más de dichos ingredientes activos.
ARP990103678A 1998-07-28 1999-07-27 Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas. AR016502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19834931A DE19834931A1 (de) 1998-07-28 1998-07-28 Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie

Publications (1)

Publication Number Publication Date
AR016502A1 true AR016502A1 (es) 2001-07-04

Family

ID=7876248

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103678A AR016502A1 (es) 1998-07-28 1999-07-27 Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas.

Country Status (28)

Country Link
US (1) US7053077B1 (es)
EP (1) EP1100509B1 (es)
JP (1) JP4891479B2 (es)
KR (1) KR20010072082A (es)
CN (1) CN1311683A (es)
AP (1) AP2001002054A0 (es)
AR (1) AR016502A1 (es)
AT (1) ATE292468T1 (es)
AU (1) AU766019B2 (es)
BG (1) BG105171A (es)
BR (1) BR9912466A (es)
CA (1) CA2338558A1 (es)
CO (1) CO5261567A1 (es)
DE (2) DE19834931A1 (es)
EA (1) EA003371B1 (es)
EE (1) EE200100053A (es)
HK (1) HK1040192A1 (es)
HU (1) HUP0102913A3 (es)
IL (1) IL141081A0 (es)
IS (1) IS5819A (es)
MX (1) MXPA01000548A (es)
NO (1) NO20010468L (es)
NZ (1) NZ509521A (es)
PL (1) PL345588A1 (es)
SK (1) SK1292001A3 (es)
TR (1) TR200100234T2 (es)
WO (1) WO2000006175A1 (es)
ZA (1) ZA200100743B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406634A1 (en) 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
US8282612B1 (en) 2008-03-07 2012-10-09 Denise H. Miller Methods and devices for intrauterine absorption
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
EP2647379A1 (en) * 2012-04-05 2013-10-09 PregLem S.A. Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9078786B1 (en) 2012-10-19 2015-07-14 Denise H. Miller Methods and devices for collecting body fluids
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314694A (en) * 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
WO1995001161A1 (en) * 1993-06-29 1995-01-12 Leiras Oy Pack for use in, and method of hormonal replacement therapy
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447714C2 (de) * 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur Hormonsubstitutions-Therapie
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
TW448049B (en) * 1997-03-05 2001-08-01 Akzo Nobel Nv Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis
AU4957999A (en) * 1998-07-17 2000-02-07 Pharmacia & Upjohn Company Subcutaneous medroxyprogesterone acetate for contraception

Also Published As

Publication number Publication date
EA003371B1 (ru) 2003-04-24
AU766019B2 (en) 2003-10-09
MXPA01000548A (es) 2002-04-08
ATE292468T1 (de) 2005-04-15
TR200100234T2 (tr) 2001-06-21
HK1040192A1 (zh) 2002-05-31
EE200100053A (et) 2002-06-17
EP1100509A1 (de) 2001-05-23
EP1100509B1 (de) 2005-04-06
DE59911879D1 (de) 2005-05-12
CO5261567A1 (es) 2003-03-31
BG105171A (bg) 2001-07-31
ZA200100743B (en) 2002-05-08
CA2338558A1 (en) 2000-02-10
BR9912466A (pt) 2001-04-17
HUP0102913A2 (hu) 2002-01-28
PL345588A1 (en) 2001-12-17
SK1292001A3 (en) 2001-07-10
NO20010468D0 (no) 2001-01-26
CN1311683A (zh) 2001-09-05
AU5148199A (en) 2000-02-21
AP2001002054A0 (en) 2001-03-31
NO20010468L (no) 2001-03-27
KR20010072082A (ko) 2001-07-31
JP2002521452A (ja) 2002-07-16
NZ509521A (en) 2003-11-28
WO2000006175A1 (de) 2000-02-10
US7053077B1 (en) 2006-05-30
EA200100108A1 (ru) 2001-12-24
DE19834931A1 (de) 2000-02-24
IL141081A0 (en) 2002-02-10
JP4891479B2 (ja) 2012-03-07
HUP0102913A3 (en) 2002-03-28
IS5819A (is) 2001-01-19

Similar Documents

Publication Publication Date Title
AR016502A1 (es) Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas.
US5521166A (en) Antiprogestin cyclophasic hormonal regimen
KR100365879B1 (ko) 프로게스테론길항제및게스타겐을포함하는자궁내막증식증또는자궁평활근종치료제
KR960001371B1 (ko) 폐경기 전의 여성용 혼합 제형 및 이를 포함하는 팩
JP3937240B2 (ja) 黄体ホルモン関連の破綻出血の最小化
NL300381I2 (nl) Estradiolvaleraat en dienogest
DE59205986D1 (de) Ovulationshemmendes Mittel zur hormonalen Kontrazeption
LU91065I2 (fr) Drospirenone en combinaison avec oestradiol et leurs dérivés pharmaceutiquement acceptables (Allurene-Angeliq)
DE59506934D1 (de) Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
Johansson et al. New delivery systems in contraception: vaginal rings
HU224818B1 (en) The use of progestogen and estrogen for manufacturing a pharmaceutical composition for substitution therapy and oral contraception
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
RU2004113305A (ru) Комбинированный эстрогенный/гестагенный препарат и его применение
RU96119957A (ru) Фармацевтический комбинированный препарат для гормональной контрацепции
ES2208518T3 (es) Medio y metodo anticonceptivo hormonal.
Luciano et al. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. A double-blind, prospective study of sequential versus continuous therapy
RU2215540C2 (ru) Схемы приема гестаген-антигестагена
RU2000115313A (ru) Схемы приема гестаген-анти-гестагена
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
US20220110947A1 (en) Cyproterone acetate compositions and uses thereof
Borrego How to select progestin for hormone replacement therapy
MXPA01010976A (es) Uso de antiprogestagenos en terapia combinada.
Collins New Progestogens: A Review of Clinical Data
AU3662300A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding

Legal Events

Date Code Title Description
FA Abandonment or withdrawal